Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2501 USD | -6.43% | -18.27% | -41.85% |
May. 23 | Theriva Biologics Gets Fast Track Designation for Pancreatic Cancer Treatment | MT |
May. 23 | Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.32M |
---|---|---|---|---|---|
Net income 2024 * | -28M | Net income 2025 * | -34M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.31
x | P/E ratio 2025 * |
-0.33
x | Employees | 22 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.16% |
Latest transcript on Theriva Biologics, Inc.
1 day | -6.43% | ||
1 week | -18.27% | ||
1 month | -37.86% | ||
3 months | -46.22% | ||
6 months | -58.25% | ||
Current year | -41.85% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 15-05-31 | |
Michael Kaleko
CTO | Chief Tech/Sci/R&D Officer | - | 12-02-29 |
- | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeff Wolf
BRD | Director/Board Member | 60 | 05-12-31 |
John Monahan
BRD | Director/Board Member | 77 | 20-11-10 |
Jeffrey Kraws
CHM | Chairman | 59 | 05-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.2501 | -6.43% | 373,108 |
24-05-30 | 0.2673 | -4.19% | 248,078 |
24-05-29 | 0.279 | +2.95% | 742,094 |
24-05-28 | 0.271 | -11.44% | 1,130,589 |
24-05-24 | 0.306 | -7.55% | 3,059,364 |
Delayed Quote Nyse, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.85% | 4.32M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- TOVX Stock